Scott L. Friedman

This study identifies Wnt9b-Sfrp2 crosstalk between endothelial and stellate cells as a driver of fibrosis resolution in MASH using single-cell and spatial profiling.

This paper introduces two novel CB2-specific agonist antibodies that reduce macrophage activation and fibrosis in vitro and an ex vivo liver model.

This study investigates how RvD1 reduces inflammation, cell death, and fibrosis in MASH by targeting Stat1, ER stress, and MMP pathways.

This study shows that mannose reduces liver steatosis and fibrosis in MASH by inhibiting fructose metabolism, offering a potential therapeutic approach.

This study evaluates in vivo anti-FAP CAR T therapy for MASH, showing reduced fibrosis and restored liver homeostasis through HSC depletion and immune modulation.

This study shows that CEACAM1 loss in hepatic stellate cells (HSCs) activates them, leading to myofibroblastic transformation and fibrosis without insulin resistance or steatosis.